Key result
Once-weekly semaglutide linked to a ~26% improvement in vascular endothelial function.
Why the study?
Once-weekly semaglutide confers clinical cardiometabolic benefits, but its effect on vascular endothelial function in Japanese patients with T2DM remains unclear.
Does once-weekly subcutaneous semaglutide improve vascular endothelial function in Japanese patients with type 2 diabetes mellitus?
Does once-weekly subcutaneous semaglutide improve vascular endothelial function in Japanese patients with type 2 diabetes mellitus?
Once-weekly semaglutide significantly improved vascular endothelial function (measured by reactive hyperemia index) in Japanese patients with type 2 diabetes, suggesting a potential mechanism for its cardiovascular protective effects.
Answers are grounded in this paper and cite their sources.
Associated endothelial gains in this T2DM cohort should not change practice; hypothesis-generating and needs RCTs to confirm.
Background: Patients with type 2 diabetes mellitus (T2DM) have a high-risk condition of developing cardiovascular disease, and therefore, therapeutic strategies should consider cardiovascular risk reduction. Previously, we demonstrated that circulating glucagon-like peptide-1 (GLP-1) levels are significantly lower in Japanese patients with coronary artery disease (CAD) compared with non-CAD subjects. Once-weekly semaglutide, a GLP-1 receptor agonist, has demonstrated clinical cardiometabolic benefits; however, its effect on vascular endothelial function in Japanese patients with T2DM remains unclear. Methods: This retrospective observational study included patients with T2DM who were hospitalized at Jinnouchi Hospital and initiated once-weekly subcutaneous semaglutide therapy since 2021. Vascular endothelial function was assessed using reactive hyperemia peripheral arterial tonometry, expressed as the reactive hyperemia index (RHI), before and after semaglutide treatment. Clinical parameters including body weight (BW), glycated hemoglobin A1c (HbA1c), low-density lipoprotein cholesterol (LDL-cho), and high-sensitivity C-reactive protein (hsCRP) were also evaluated. Results: A total of 24 patients (mean age: 55 years; n=20 (83.3%) male) were included. RHI significantly increased following semaglutide therapy (baseline: 1.62±0.19 versus follow-up: 2.04±0.60; p<0.01). BW, HbA1c, and LDL-cho also showed significant reductions (all p<0.01). HsCRP tended to decrease, though not significantly. None of the changes in BW, HbA1c, LDL-cho, or hsCRP correlated with the changes in RHI. Conclusion: Once-weekly semaglutide treatment significantly provided potential improvement in vascular endothelial function in Japanese patients with T2DM, supporting the cardiovascular protective role of semaglutide therapy in the clinical management of T2DM.
No takes yet. Share an insight, caveat, or question.
Sugiyama et al. (2025) studied this question. Once-weekly semaglutide treatment improved vascular endothelial function, as indicated by an increase in reactive hyperemia index from 1.62 to 2.04.
Synapse has enriched 10 related papers. Consider them for comparative context: